Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis

Links shared publicly online about this topic.

263
total visits

Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics' site-specific TheraPEG PEGylation technology to develop NU400, a long-acting version of Nuron's proprietary recombinant human interferon beta-1b.

View full resource at news-medical.net

Tags: Vaccination, Multiple Sclerosis, Multiple Sclerosis Medication, Biotech, Vaccine, Betaseron, Betaferon